BIO 2021 Notebook: Looking Past The Pandemic
Annual Meeting Focuses On Post-COVID R&D, Politics And New Opportunities
News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic.
You may also be interested in...
Stakeholders believe virtual meetings should remain an option going forward, but that in-person sessions should still be convened in many cases.
The green light for the COVID-19 antibody therapy is welcome news for the partners, but rising vaccination rates plus three other competitors in Europe will limit revenues.
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.